secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088584
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood posts Q2 GAAP net loss of $1.06B on acquisition costs; LINZESS sales +9%
--------------------------------------------------------------------------------

- GAAP net loss attributable to Ironwood of $1.06B, or $6.84/share diluted, primarily from VectivBio acquisition.
- Total revenues $107.4M, up 10% YoY; LINZESS U.S. net sales $270M, +9% YoY.
- FDA approved LINZESS for pediatric FC ages 6-17 in June, expanding addressable market.
- Acquired VectivBio for apraglutide (SBS-IF); STARS Phase III enrollment complete, data March 2024.
- Raised full-year 2023 guidance: LINZESS net sales $1.055-1.075B, Ironwood revenue $435-455M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/0001104659-23-088584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923088584/tm2323024d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer